Skip to main content
. 2021 Feb 8;315(2):2057–2088. doi: 10.1007/s10479-021-03961-0

Table 4.

Optimal flow of Midazolam to pharmacies (t = 1, 2, 3)

Brand Pharmacy No competition Competitive market
Product flow in each period Product flow in each period
1 2 3 1 2 3
Actoverco 1 660 1100 965 1525
2 725 1150 955 1440
3 1155 1510 1155 1510
4 445 895 450 250 747 250
5 379 695 455 116 303 200
6 395 800 390 342 685 342
7 385 850 360 510 1170 505
Abidi 1 665 1110 360 685
2 725 1140 495 850
3 1155 1500 1155 1500
4 445 895 450 640 1042 650
5 380 695 460 642 1085 715
6 400 795 400 456 914 456
7 385 750 370 260 430 225
HHS Vulnerability Disclosure